InvestSMART

Clever Culture Systems Limited (ASX:CC5)

ALERT: Price-sensitive ASX Announcement for CC5
Current share price for CC5 : $0.018 -0.012 (-40%)+
Announcement
Release
30 Oct 2025 9:20AM
Price at Release
$0.030
Full Release
download
Summary
Clever Culture Systems Ltd, an Australian company specializing in microbiology automation, released its Quarterly Activities and Appendix 4C Cash Flow Report for the quarter ended 30 September 2025. The company reported strong momentum into FY25, securing new customers such as Novo Nordisk and Boehringer Ingelheim for their APAS® Independence technology, which utilizes AI for microbiology automation. The company completed installations for AstraZeneca and Bristol Myers Squibb, increasing their customer base to seven major pharmaceutical companies. During the quarter, CCS launched a new contact plate analysis module, enhancing the capabilities of APAS® Independence and driving increased adoption and revenue. Financially, the company reported a positive cash flow with a balance of $1.4 million and projected cash inflows of $4.1 million over the next two quarters. The company also saw significant cash inflows from the exercise of options and reported a net increase in cash and cash equivalents for the period.
Key Points
  • Clever Culture Systems Ltd released its quarterly cash flow report for the quarter ended 30 September 2025.
  • The company reported securing new customers including Novo Nordisk and Boehringer Ingelheim.
  • APAS® Independence technology installations were completed for AstraZeneca and Bristol Myers Squibb.
  • A new contact plate analysis module was launched, enhancing APAS® capabilities.
  • The company has a positive financial outlook with a cash balance of $1.4 million.
  • Projected cash inflows are expected to be $4.1 million over the next two quarters.
  • The company saw cash inflows from the exercise of options.
  • Net cash inflows for the quarter were reported at $0.2 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.